What is the potential for overdiagnosis of heparin‐induced thrombocytopenia?
Top Cited Papers
Open Access
- 1 November 2007
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 82 (12), 1037-1043
- https://doi.org/10.1002/ajh.21032
Abstract
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize platelet factor 4//heparin (PF4/H) complexes. According to the “iceberg model,” only a subset of anti-PF4/heparin antibodies of IgG class evincing strong platelet-activating properties cause clinical HIT. Since many centers rely predominantly on an anti-PF4/polyanion enzyme-immunoassay (EIA) to diagnose HIT, we estimated the potential for overdiagnosis when only this single test is available. We examined a database of 100 patients in whom the probability of HIT had been estimated using a clinical scoring system (4Ts), and where patients underwent systematic testing for HIT antibodies using three assays: the platelet serotonin release assay (SRA), an “in-house” EIA that detects IgG anti-PF4/heparin antibodies (EIA-IgG), and a commercial EIA that detects anti-PF4/polyanion antibodies of all three immunoglobulin classes (EIA-GTI). Whereas 16 of 100 patients fulfilled a “classic” definition of HIT (intermediate/high probability plus strong platelet-activating anti-PF4/heparin IgG antibodies), an additional 16 patients fulfilled a “liberal” definition in which any investigated patient (irrespective of the pretest probability) who had a positive EIA-GTI was considered to have HIT. The clinical features of these 16 additional patients—including generally weak antibodies and low risk for thrombosis—suggest underlying non-HIT explanations for thrombocytopenia. Patients with a positive SRA generally corresponded to those with intermediate or high pretest probability of HIT who also had strong EIA-GTI reactivity (>1.20 OD units). We conclude there is the potential to overdiagnose HIT by ∼100% if any positive EIA is considered to “confirm” the diagnosis of HIT irrespective of the clinical scenario. Am. J. Hematol., 2007.This publication has 19 references indexed in Scilit:
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopeniaEuropean Journal of Haematology, 2006
- Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?Journal of Laboratory and Clinical Medicine, 2005
- No significant improvement in diagnostic specificity of an anti‐PF4/polyanion immunoassay with use of high heparin confirmatory procedureJournal of Thrombosis and Haemostasis, 2005
- Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopeniaBlood, 2005
- Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosisThrombosis and Haemostasis, 2005
- Thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2004
- Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosisJournal of Laboratory and Clinical Medicine, 2001
- Prevalence of Heparin-Associated Antibodies Without Thrombosis in Patients Undergoing Cardiopulmonary Bypass SurgeryCirculation, 1997
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinThe New England Journal of Medicine, 1995